RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The global pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), named coronavirus disease 2019, has infected more than 8.9 million people worldwide. This calls for urgent effective therapeutic measures. RNA‐dependent RNA polymerase (RdRp) activity in viral transcription and replication has been recognized as an attractive target to design novel antiviral strategies. Although SARS‐CoV‐2 shares less genetic similarity with SARS‐CoV (~79%) and Middle East respiratory syndrome coronavirus (~50%), the respective RdRps of the three coronaviruses are highly conserved, suggesting that RdRp is a good broad‐spectrum antiviral target for coronaviruses. In this review, we discuss the antiviral potential of RdRp inhibitors (mainly nucleoside analogs) with an aim to provide a comprehensive account of drug discovery on SARS‐CoV‐2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Virtual screening of chemical libraries
Shoichet, B. K. (2004) · Nature · doi:10.1038/nature03197 · Cited by 1,425
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., et al. (2020) · doi:10.1101/2020.03.17.20037432 · Cited by 852 · cited 1×
“(ChiCTR2000030254), FPV showed superior efficacy to treat moderate COVID‐19 pneumonia as compared with Arbidol (umifenovir, a membrane fusion inhibitor).(73) In a small‐scale non‐randomized controlled study at The Third People's Hospital of Shenzhen”
BackgroundCare of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
Boettler, T., Newsome, P. N., Mondelli, M. U., Maticic, M., Cordero, E., Cornberg, M., & Berg, T. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100113 · Cited by 477
Boosting docking-based virtual screening with deep learning.
Pereira, J. C., Caffarena, E. R., & dos Santos, C. N. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00355 · Cited by 395
High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses.
Shen, L., Niu, J., Wang, C., Huang, B., Wang, W., Zhu, N., Deng, Y., Wang, H., Ye, F., Cen, S., et al. (2019) · Journal of Virology · doi:10.1128/jvi.00023-19 · Cited by 319
Cited by
Sacco, M. D., Ma, C., Lagarias, P., Gao, A., Townsend, J. A., Meng, X., Dube, P., Zhang, X., Hu, Y., Kitamura, N., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe0751 · Cited by 385
Koulgi, S., Jani, V., V N, M. U., Sonavane, U., & Joshi, R. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1894985 · Cited by 12
Munawaroh, H. S. H., Gumilar, G. G., Pratiwi, R. N., Khoiriah, S. F., Ningrum, A., Martha, L., Chew, K. W., & Show, P.-L. (2024) · Algal Research · doi:10.1016/j.algal.2024.103468 · Cited by 9
Koulgi, S., Jani, V., Uppuladinne V N, M., Sonavane, U., & Joshi, R. (2020) · doi:10.26434/chemrxiv.12886856
Metadata
- Authors
- Wang, Y., Anirudhan, V., Du, R., Cui, Q., & Rong, L.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2020-07-19
- Volume
- 93
- Issue
- 1
- Pages
- 300-310
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W3038463632
- Cited by
- 115
- References
- 10
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target. https://app.cochat.ai/papers/10.1002/jmv.26264
- The paper
- Wang, Y., Anirudhan, V., Du, R., Cui, Q., & Rong, L. (2021). RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target. Journal of Medical Virology. https://doi.org/10.1002/jmv.26264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.